Marlborough biomedical firm Boston Scientific now has a device the company says can predict impending heart failure.Â
A study by the company has found its HeartLogic Heart Failure Diagnostic continuously receives data from the heart by evaluating heart sounds, respiration rate and volume, thoracic impedance heart rate and activity, and when combined with blood tests, can more accurately determine when a patient is at an elevated risk of heart failure, the company said in a press release Tuesday.
Current clinical guidelines recommend the use of a blood test in order to diagnose heart failure of determine severity of a patient’s heart disease.
However, such blood tests only capture a snapshot of the heart’s condition at the time of the blood draw. The new device provides expanded ability of a baseline blood test to identify when patients were at an elevated risk of heart failure, the company said.
When combined, the two methods accurately identified when patients in a variety of risk groups were at a 23- to 50-times increased risk of heart failure, Boston Scientific said.
The one-year study included 900 patients who had enhanced sensor data collection enabled in their cardiac resynchronization therapy defibrillator.
The company received U.S. Food and Drug Administration approval earlier this year, and devices will be commercially available later this year, the company said.
